Orchestra BioMed Holdings, Inc. has reported a significant stock purchase by one of its directors, David Pacitti. On November 9, 2026, Pacitti acquired 20,000 shares of the company's common stock at a price of $5.00 per share. This transaction is notable as it reflects a strong belief in the company's growth potential in the surgical and medical instruments and apparatus sector.

Following this purchase, Pacitti now holds a total of 74,750 shares in Orchestra BioMed. The acquisition was made through an underwritten public offering, indicating a structured approach to raising capital and enhancing shareholder value.

Background

Orchestra BioMed Holdings, Inc. operates in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company is publicly traded on the Nasdaq under the ticker symbol OBIO. It is categorized as a non-accelerated filer and a smaller reporting company. Recent filings include a Schedule 13D/A and several Form 4 submissions, indicating ongoing activity in the company's stock transactions.

What the Filing Says

The filing states, "These shares were purchased in an underwritten public offering of the Issuer at the public offering price of $5.00 per share." This highlights the structured nature of the transaction and the confidence in the company's market position.

Impact

This stock purchase may affect various stakeholders, including current shareholders and potential investors. The increase in Pacitti's holdings could be interpreted as a vote of confidence in Orchestra BioMed's strategic direction and future performance.

What's Next

The filing does not say what happens next.